FDA Approves Pfizer's RSV Shot for Older Adults, Abrysvo
Medically reviewed by Drugs.com.
By Cara Murez HealthDay Reporter
THURSDAY, June 1, 2023 -- Older adults may have a second vaccine option for RSV following the U.S. Food and Drug Administration's approval of a Pfizer vaccine on Wednesday.
The other shot for adults 60 and up is made by GSK. It was approved May 3.
Both should be available by fall, before the seasonal spread of respiratory syncytial virus (RSV), The New York Times reported.
The Pfizer vaccine, known as Abrysvo, has effectiveness of nearly 67% when a patient has two symptoms of RSV, such as a sore throat and cough. It's 86% effective when three or more symptoms surface.
Its GSK competitor — named Arexvy — was about 83% effective against severe RSV, the Times reported.
The study on the Pfizer vaccine did include a concern about autoimmune syndromes. One patient among the 34,000 who received the vaccine in the study developed a life-threatening case of Guillain-Barré syndrome a week after receiving the shot. Another developed Miller Fisher syndrome, which is a subtype of that condition.
That means the incidence rate for these syndromes is 1 in 9,000, higher than the 1 in 100,000 seen in the general population.
FDA advisors voted 7 to 4 in favor of the vaccine’s safety and efficacy. It had voted 10 to 2 for the GSK vaccine, which was linked to similar cases.
Advisers for the U.S. Centers for Disease Control and Prevention will meet this month to talk about their recommendations for health care providers. They have suggested that the vaccines may be recommended for those aged 65 and older, according to the Times.
The vaccines come after a winter season in which COVID-19, the flu and RSV all spread. While RSV infection is generally mild and cold-like in healthy people, it can be fatal in infants and the elderly. In the United States, about 60,000 adults aged 65 and up are hospitalized with RSV, and 6,000 to 10,000 die each year, the FDA estimated.
To prevent one of these deaths, about 21,000 to 25,000 older adults would have to be vaccinated against RSV, depending on the vaccine.
Seniors on Medicaid and Medicare will not have a co-pay for a vaccine deemed medically necessary, a Pfizer spokeswoman said.
Sources
- The New York Times
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2023
Read this next
School Entry Rules Boost Kids' HPV Vaccination Rates
WEDNESDAY, May 1, 2024 -- Getting the HPV shot in adolescence can spare kids a lifetime of risk for cervical and other cancers related to the virus, but only half of American kids...
Painless Skin Patch Could Deliver Vaccines to Kids
TUESDAY, April 30, 2024 -- Kids who don’t like vaccination shots might soon have an alternative in a painless skin patch, researchers say. More than 90% of 190 Gambian...
Vaccines Have Saved 154 Million Lives, Mostly Babies, Over Past 50 Years
MONDAY, April 29, 2024 -- Global vaccination efforts have saved an estimated 154 million lives, including 101 million infants, a new study led by the World Health Organization...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
